A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
Trial details
- Registry ID
- NCT06319456
- Phase
- Phase 3
The FDA approved Acalabrutinib on 31 Oct 2017.
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.NCT06319456 | Ascentage Pharma Group Inc. | Phase 3 | Recruiting | 2027-08Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2017-10-31Day | Acalabrutinib | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA210259", "applicant_as_listed_by_fda": "ASTRAZENECA", "brand_names": ["CALQUENCE"], "active_ingredients": ["ACALABRUTINIB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20171031", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |